456 Studies Now Enrolling
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
A study for patients with Acute Myeloid Leukemia (AML) using study drug ASP2215
| Sponsor: | Astellas |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ5660 |
| U.S. Govt. ID: | NCT02421939 |
| Contact: | Joseph Jurcic: 646-317-5077 / jgj2110@cumc.columbia.edu |
Additional Study Information:
The purpose of the study is to see if a medicine called ASP2215 is both effective and safe as atreatment for AML patients with mutations in FLT3 gene identified by an investigational FLT3Mutation Assay companion diagnostic (a specific way to test your blood or bone marrow, which is used to see if you have a mutation of the FLT3 gene), compared to salvage chemotherapy.
This study is closed
